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ABSTRACT
Introduction: The emergence of multidrug resistant
(MDR) Gram-negative bacteria (GNB), including
carbapenemase-producing strains, has become a major
therapeutic challenge. These MDR isolates are often
involved in complicated urinary tract infection (cUTI),
and are associated with poor clinical outcomes. The
study has been designed to gain insight into the
epidemiology, clinical management, outcome and
healthcare cost of patients with cUTI, especially in
countries with high prevalence of MDR GNB.
Methods and analysis: This multinational and
multicentre observational, retrospective study will
identify cases from 1 January 2013 to 31 December
2014 in order to collect data on patients with cUTI as a
cause of hospital admission, and patients who develop
cUTI during their hospital stay. The primary end point
will be treatment failure defined as the presence of any
of the following criteria: (1) signs or symptoms of
cUTI present at diagnosis that have not improved by
days 5–7 with appropriate antibiotic therapy, (2) new
cUTI-related symptoms that have developed within
30 days of diagnosis, (3) urine culture taken within
30 days of diagnosis, either during or after completion
of therapy, that grows ≥104 colony-forming unit/mL of
the original pathogen and (4) death irrespective of
cause within 30 days of the cUTI diagnosis.
Sample size: 1000 patients afford a power of 0.83
(α=0.05) to detect an absolute difference of 10% in the
treatment failure rate between MDR bacteria and other
pathogens. This should allow for the introduction of about
20 independent risk factors (or their interaction) in a
logistic regression model looking at risk factors for failure.
Ethics and dissemination: Approval will be sought
from all relevant Research Ethics Committees. Publication
of this study will be considered as a joint publication by
the participating investigator leads, and will follow the
recommendations of the International Committee of
Medical Journal Editors (ICMJE).
Trial registration number: NCT02641015; Pre-results.
Strengths and limitations of this study
▪ The study has been designed by a multinational
team. The team members have worked collabora-
tively to determine the data to be collected. The
multinational team approach to the design of the
study and data set has made the study more
likely to succeed in collecting data in a number
of different countries than if it had been
designed for just one country.
▪ The study will increase knowledge of the clinical
picture, epidemiology and outcomes of hospita-
lised patients with complicated urinary tract
infection (cUTI) caused by multidrug resistant
Gram-negative bacteria. The identification of
modifiable risk factors might lead to suggestion
of changes in practice that could reduce the inci-
dence of cUTI.
▪ The study also aims to calculate costs relating to
cUTI which are currently unknown.
▪ The retrospective nature of the study design
means that it is only possible to collect informa-
tion that is still available on paper or electronic-
ally. Inevitably, some information may have been
lost or has never been recorded.
▪ The study is also reliant on proper documenta-
tion of signs and symptoms of urinary tract
infections and outcome data for up to 2 months
subsequent to discharge; however, this is not
always available in some sites.
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INTRODUCTION
Bacterial resistance to antimicrobial agents has been
identiﬁed in the European Union and many other coun-
tries as a major public health problem.1–4 Prompt action
is a clear priority nationally and internationally. Most dis-
turbing is the rapid emergence and dissemination of
resistance to third generation cephalosporins in
Escherichia coli and Klebsiella pneumoniae, primarily due to
the production of extended spectrum β-lactamases,
which are frequently seen in association with resistance
to other classes of antibiotics.3 5 6 These multidrug resist-
ant (MDR) isolates7 are particularly prevalent in hospital
practice, and are associated with increased morbidity
and mortality in infections such as complicated urinary
tract infections (cUTIs) and healthcare-associated infec-
tions (HAIs).8–12 Patients with MDR E. coli or K. pneumo-
niae are frequently treated with carbapenems. However,
there is an increasing number of MDR isolates that are
also carbapenemase producers. Therefore, for an
increasing number of patients with life-threatening infec-
tions due to E. coli and K. pneumoniae there are few
therapeutic options.13 As well as a rapid increase in the
prevalence of MDR E. coli and K. pneumoniae, there has
been a rise in the prevalence of MDR Pseudomonas aeru-
ginosa, with more than three-quarters of European coun-
tries reporting MDR rates of >10% in invasive isolates.3 4
Urinary tract infections (UTIs) are highly prevalent
worldwide. In patients with cUTI these are frequently
caused by MDR Gram-negative bacteria (GNB).14 15
Currently, there is a lack of information about the
burden of this disease. Reports from the USA show that
in early 2000 this disease accounted for more than
100 000 hospital admissions annually, often as a result of
pyelonephritis.16 Data from Europe are limited, although
the last point prevalence survey of European acute care
hospitals demonstrated that the prevalence of HAIs was
6%. This represents ∼80 000 patients on any given day in
European acute care hospitals. Of these, UTI was the
third most common infection (19%). Enterobacteriaceae
were the most frequently isolated micro-organisms in
UTI. Overall, Enterobacteriaceae prevalence resistant to
third-generation cephalosporins in the study was 33.4%,
and 7.3% to carbapenems.17 Additionally, the presenta-
tion of patients with cUTI is changing over time; patients
are older, with a high prevalence of chronic renal failure
and other chronic diseases, instrumentation of the
urinary tract and polypharmacy. Therefore, there is a
need for contemporary data on the management,
response to treatment and outcome of patients with cUTI
against a background of increasing antibiotic resistance
and signiﬁcant changes in patients’ characteristics.
RATIONALE
Considering the lack of contemporary data on hospita-
lised patients with cUTI, increasing the knowledge can
be useful for improving clinical management, and also
for formulating research questions.
This study will especially focus on (1) patients at high
risk of infections caused by MDR pathogens, (2) the
clinical management during hospitalisation, (3) the
impact of inappropriate empirical antibiotic treatment,
(4) the risk factors for adverse outcomes, particularly
those that could be modiﬁable and (5) the costs of
cUTI for healthcare systems.
Primary objective
To determine the outcome of hospitalised patients with
cUTI and identify the risk factors associated with treat-
ment failure.
Secondary objectives
1. To identify clinical characteristics and demographic
factors of hospitalised patients with cUTI.
2. To identify the main causative MDR GNB, and their
most frequent resistance proﬁles.
3. To deﬁne risk factors associated with cUTI caused
by MDR GNB.
4. To describe clinical management of hospitalised
patients with cUTI.
5. To determine the modiﬁable risk factors associated
with early treatment failure in patients with cUTI.
6. To determine length of hospital stay in patients with
cUTI.
7. To determine duration of antibiotic therapy (intra-
venous, intramuscular and oral) in patients with
cUTI.
8. To determine mortality rate of hospitalised patients
with cUTI.
9. To estimate the cost per case of cUTI measured by
length of hospital stay, intensive care unit require-
ments, medications, tests and need for urological
intervention and haemodialysis.
10. To estimate the total national cost of illness due to
cUTI in participating countries.
11. To help identify patient types, and potential clinical
trial sites for future phase 2 or 3 clinical trials in
cUTI.
METHODS AND ANALYSIS
Study design
A multinational and multicentre retrospective, observa-
tional cohort study which will involve the collection of
data on hospitalised patients from 1 January 2013 to 31
December 2014.
Study population
Data will be collected on patients who had a diagnosis of
cUTI as the primary cause of hospitalisation, and
patients hospitalised for another reason but who devel-
oped cUTI during their hospitalisation.
Setting
The study will be conducted in Bulgaria, Greece,
Hungary, Israel, Italy, Romania, Spain and Turkey.
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The number of sites per country will be identiﬁed via the
Clinical Trial Network (CLIN-NET), and be included in
the study.
Selection of cases
Patients will be identiﬁed by searching for any of the fol-
lowing International Classiﬁcation of Diseases (ICD)-9
Clinical Modiﬁcation (CM) or ICD-10 CM Codes18 19 at
discharge on the hospital administration system:
ICD-9 CM Codes: 590.1, 590.10, 590.11, 590.2, 590.8,
590.80, 590.9, 595.0, 595.89, 595.9, 599.0;
ICD-10 CM Codes: N10, N12, N13.6, N15.1, N15.9,
N30.0, N30.8, N30.9, N39.0.
In order to avoid selection bias, all consecutive
patients who have ICD-9 or ICD-10 CM codes will be
reviewed at each site. All patients who meet the inclu-
sion criteria will be selected for data collection.
Inclusion criteria
1. The following criteria, which have been adapted from
Food and Drug Administration (FDA) guidance on
cUTIs: Developing Drugs for Treatment. Guidance for
Industry;20 European Medicines Agency (EMA) guide-
lines on the evaluation of medicinal products indi-
cated for treatment of bacterial infections;21 and
clinical practice guidelines for the evaluation and
management of chronic kidney disease22 must be met
to qualify for enrolment into this study: patients with
UTI and at least one of the following:
▸ Indwelling urinary catheter;
▸ Urinary retention (at least 100 mL of residual
urine after voiding);
▸ Neurogenic bladder;
▸ Obstructive uropathy (eg, nephrolithiasis,
ﬁbrosis);
▸ Renal impairment caused by intrinsic renal
disease: estimated glomerular ﬁltration rate
<60 mL/min;
▸ Renal transplantation;
▸ Urinary tract modiﬁcations, such as an ileal loop
or pouch;15
▸ Pyelonephritis and normal urinary tract anatomy.
2. And at least one of the following signs or symptoms:
▸ Chills or rigors associated with fever or hypother-
mia (temperature >38°C or below 36°C);
▸ Flank pain (pyelonephritis) or pelvic pain
(cUTI);
▸ Dysuria, urinary frequency or urinary urgency;
▸ Costovertebral angle tenderness on physical
examination;
▸ UTI-related altered mental state.
3. And urine culture with at least 105 colony-forming
unit (CFU)/mL or greater of a uropathogen (no
more than two species); or
4. At least one blood culture growing possible uropatho-
gens (no more than two species) with no other
evident site of infection.
If a patient has more than one episode of cUTI during
the same hospitalisation, only the ﬁrst episode will be
included. Recurrence within 30 days will be considered
as treatment failure.
Exclusion criteria
If any of the following exclusion criteria apply, the
patient is not eligible for enrolment into this study:
1. Patients <18 years of age;
2. Prostatitis;
3. Polymicrobial infections that include Candida spp;
4. Polymicrobial infections that include more than two
bacterial species;
5. cUTI with Candida spp. as sole uropathogen.
Definition of MDR bacteria
Bacterial multidrug resistance is deﬁned as acquired
non-susceptibility to at least one agent in three or more
antimicrobial categories according to the international
expert proposal published by Magiorakos et al.7
Data collection
For patients recruited into the study, data will be col-
lected retrospectively. These data items will be obtained
from different sources, including the patient notes, elec-
tronic patient records, the hospital patient administra-
tion system and the hospital laboratory systems.
For all patients, a standardised set of information will
be recorded. This will include demographics, comorbid-
ities including those required to calculate a modiﬁed
Charlson score,23 functional capacity,24 place of acquisi-
tion of infection, predisposing risk factors, clinical data,
clinical pathology data, microbiological data, imaging
test data, infection management, antibiotic therapy, out-
comes, details of discharge and readmission.
Participant timeline
The follow-up period will be for up to 2 months after
discharge from the admitting hospital.
OUTCOMES
Primary end point
The primary end point will be treatment failure, apply-
ing a slightly modiﬁed deﬁnition of FDA guidance on
cUTIs: Developing Drugs for Treatment. Guidance for
Industry.20
This deﬁnition includes any of the following
conditions:
▸ Signs or symptoms of cUTI present at diagnosis that
have not improved by days 5–7 with appropriate anti-
biotic therapy;
▸ New cUTI-related symptoms that have developed
within 30 days of the original cUTI diagnosis;
▸ Urine culture taken within 30 days of the original
cUTI diagnosis, either during or after completion of
therapy, that grows ≥104 CFU/mL of the original
pathogen identiﬁed in the diagnostic sample;
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▸ Death irrespective of cause within 30 days of the ori-
ginal cUTI diagnosis.
Secondary end points
The following secondary end points will be evaluated:
▸ Time to clinical response, in days;
▸ Time to urological intervention for source control, in
days;
▸ Time to death, in days;
▸ Duration of antibiotic therapy, in days;
▸ Length of hospital stay, in days;
▸ In-hospital mortality;
▸ All-cause mortality within 30 days of the original cUTI
diagnosis;
▸ All-cause mortality for 2 months after hospital
discharge;
▸ Cost per case of cUTI;
▸ Readmissions to the hospital within 60 days of hos-
pital discharge;
▸ Adverse events related to antibiotic treatment includ-
ing moderate or severe allergic reactions, severe renal
impairment, Clostridium difﬁcile infection.
Health economic analysis
We will evaluate the cost of cUTI in participating coun-
tries, and the factors affecting these costs. The perspec-
tive will be the hospital provider, as this is where the
majority of the cost burden of cUTI is expected to
fall.25 26 This will have three components:
1. We will estimate the cost per case of cUTI in partici-
pating countries. This will be based on collection of
healthcare resource use data on length of hospital
stay in different settings, medications and other treat-
ment for infection, tests, and need of urological
intervention and haemodialysis. Unit cost data for
each cost component will be collected for each par-
ticipating country from published and administrative
sources, and multiplied by volume of resource used,
and then summed across all components to calculate
the costs per patient for cUTI caused by MDR GNB.
Findings will be presented as means (with 95% CIs)
and medians (with IQRs) of total costs, and also for
each separate cost component.
2. Using data collected in this programme plus supple-
mentary epidemiological data, the incidence of cUTI
caused by MDR GNB in each country will be mod-
elled and this will be multiplied by the mean incre-
mental cost per patient to compute the total national
cost of illness of cUTI caused by MDR GNB.
3. Multivariate regression analysis using patient-level
cost data to investigate the factors associated with
healthcare costs will be undertaken. The dependent
variable will be mean costs per patient described
under 1, given above. Independent variables will
include age, gender, comorbidities, severity of infec-
tion, whether or not the patient died, signs and symp-
toms of UTI, and where the infection was acquired.
To account for skewness of the cost data, a
generalised linear model with γ family and log link27
will be used. The impact of unobserved heterogeneity
due to the hierarchical structure of the data (patients
within hospitals within countries) will be explored
and accounted for by considering the hospital and
country ﬁxed-effects and random-effects models.
Sample size
One thousand patients should afford a power of 0.83
(α=0.05) to detect an absolute difference of 10% in the
treatment failure rate between MDR bacteria and other
pathogens. This should allow for the introduction of
about 20 independent risk factors (or their interaction)
in a logistic regression model looking at risk factors for
failure.
Statistical analysis
The χ2 or Fisher’s exact tests will be used to compare cat-
egorical data, and the Student’s t-test or Mann-Whitney U
test for continuous data, as appropriate (the
Kolmogorov-Smirnoff test will be used to test whether the
distribution of continuous variable is normal). Logistic
regression analysis will be performed to identify independ-
ent variables associated with treatment failure. Variables
with p<0.10 in univariate analysis (and variables that
make clinical sense) will be included in the multivariate
model to control for confounding. The adequacy of the
ﬁnal model will be tested using the Hosmer-Lemeshow
goodness-of-ﬁt test. All tests will be two-tailed, and a
p<0.05 will be considered as statistically signiﬁcant.
Time to appropriate therapy, clinical response, uro-
logical intervention for source control or death will be
examined using competing risks.
Monitoring plans
At each site, a screening log will be kept of the patients
who were detected according to the ICD codes, and
detail the excluded patients and the reasons for
exclusion.
For conﬁrmation of the data quality and to avoid
fraud, study sites will be monitored and/or audited.
Monitoring and audit visits will be conducted by a
designated third party. Spot check monitoring and
source data veriﬁcation will be conducted to conﬁrm
that the data entered in the database are retrieved
from actual patients and their corresponding hospital
ﬁles, and has been transferred correctly. All sites’ study-
related documents, including patient data source docu-
ments, will have to be made available for monitoring
and audit.
ETHICAL ISSUES
The study will only use data routinely collected in the
time frame January 2013 to December 2014. No extra
tests or interventions will be undertaken on patients,
and there will be no impact on patient care or outcome.
Prior to initiation of a study site, approval will be sought
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from all appropriate regulatory agencies and local
Research Ethics Committees (REC) to conduct the study
in accordance with local regulatory requirements at each
site.
The processing of the patients’ personal data collected
in this study will comply with the European Directive on
the Privacy of Data. All data to be collected, stored and
processed will be anonymised (EU Directive 95/46/
EC).28
All study-related documents will be retained on site in
a secure location. No personal information will be
stored on local computers during conduct of the study
or after completion.
For data collection, an access controlled web-based
electronic case report form (eCRF) will be used. Access
to the eCRF, for data entry as well as change of any data
ﬁelds, will be overviewed by an audit trail.
This study received ﬁrst approval on 10 September
2015 by the REC of Bellvitge University Hospital. The
informed consent form and information sheet were
waived because of the retrospective nature of the study.
PUBLICATION PLANS
It is mandatory that the ﬁrst publication is based on data
from all sites, analysed as stipulated in the protocol by
statisticians/epidemiologists, and in agreement with the
COMBACTE-MAGNET publication policy. The investiga-
tor/research leads must agree not to present data gath-
ered from one site or a small group of sites before the
full initial publication and subsequently, only on agree-
ment with the Scientiﬁc Committee Board and
COMBACTE-MAGNET consortium. Any formal presen-
tation or publication of data collected from this study
will be considered as a joint publication by the partici-
pating investigator/research leads, and will follow the
recommendations of the International Committee of
Medical Journal Editors (ICMJE). Results will be
reported in accordance with STROBE guidelines.
DISCUSSION
cUTIs are common and frequently caused by MDR
GNB, which are increasingly difﬁcult to treat. Moreover,
patients with cUTI are changing over time; they are
older, with a high prevalence of chronic renal failure
and other chronic diseases, instrumentation of the
urinary tract and polypharmacy. The study aims to
improve knowledge regarding the management, res-
ponse to treatment and outcome of patients with cUTI
in European countries with high prevalence of MDR
GNB. The main objective is to identify possible modiﬁ-
able risk factors for treatment failure, especially those
related to antibiotic therapy.
Expected impact: The study will increase knowledge of
the epidemiology, clinical characteristics and outcomes
of hospitalised patients with cUTI caused by MDR GNB,
and will also assist in the selection of sites for future clin-
ical trials with antimicrobial agents.
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